Close Menu

Syngenta

In Nature this week: CRISPR-based method to determine specificity of adenine base editors, haploid induction for genome editing of commercial crops, and more.

Syngenta will be able to use the platform to evaluate, predict, compare, and select the best genetic makeup for crop molecular breeding and genomic selection.

Syngenta said that it is using CRISPR-Cas9 in multiple crops including corn, wheat, tomato, rice, and sunflower.

The multi-year deal focuses on the development of crop-protection technologies.

NEW YORK (GenomeWeb) – Roughly two years after it agreed to pay $518 million for Devgen and its portfolio of agricultural RNAi technologies, Syngenta announced this month that it is collaborating with Australian startup Nexgen to develop virus-resistant crop plants through microRNA targeting.

NEW YORK (GenomeWeb News) – Plant genomics company Evogene today announced an extension of its deal with Syngenta aimed at developing soybeans resistant to a plant parasite nematode.

Australian expressed RNAi firm Benitec Biopharma provided an update on its research and development activities late last month, reporting that it remains on track to move its lead drug candidate, the hepatitis C therapy TT-034, into the clinic as early as this month.

NEW YORK (GenomeWeb News) – Berlin-based biotech-firm Caprotec Bioanalytics said today that it has entered a research agreement with Syngenta to profile the interactions of one of Syngenta's active compounds with the proteome of certain relevant plant systems.

NEW YORK (GenomeWeb News) – Saladax Biomedical said this week that it plans to open a CLIA lab at its headquarters in Bethlehem, Pa. The firm has applied for approval from both the State of Pennsylvania and the federal government and is targeting a launch next year.

As the interest of ag-bio firms in RNAi and microRNA technologies heats up, crop sciences firm Syngenta has made an all-cash bid to acquire Devgen and its portfolio of RNAi-based crop-enhancement and -protection technologies.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.